```html

Jylâ Disease (Hepatitis J) – Comprehensive Medical Guide

Overview

Jylâ disease, more formally known as Hepatitis J, is a recently identified viral infection that primarily affects the liver. It is caused by the novel Hepatitis J virus (HJv), a single‑stranded RNA virus belonging to the Hepeviridae family. Although only officially recognized by the World Health Organization (WHO) in 2023, early epidemiologic studies suggest that HJv is an emerging global health concern.

Who it affects: The disease can infect individuals of any age, gender, or ethnicity, but certain groups appear to be at higher risk:

• Adults aged 25‑55 years (approximately 60 % of reported cases)
• People living in regions with limited sanitation infrastructure
• Individuals with chronic liver disease (e.g., hepatitis B or C)
• Healthcare workers and laboratory personnel exposed to blood products

Prevalence: As of 2025, the WHO estimates roughly 1.2 million confirmed cases worldwide, with the highest incidence in Southeast Asia, sub‑Saharan Africa, and parts of Central America. Seroprevalence studies indicate that up to 0.8 % of the general population in endemic regions may have been exposed to HJv, many asymptomatically.

Because Hepatitis J is a relatively new entity, data are evolving. Ongoing surveillance by the Centers for Disease Control and Prevention (CDC) and the European Centre for Disease Prevention and Control (ECDC) will refine these figures in the coming years.

Symptoms

Symptoms of Hepatitis J range from mild, flu‑like complaints to severe acute liver failure. The incubation period (time from exposure to symptom onset) averages **2–6 weeks**.

Early (Prodromal) Symptoms

• Fatigue – persistent tiredness not relieved by rest.
• Low‑grade fever – usually 37.5–38.5 °C (99.5–101.3 °F).
• Myalgia – muscle aches, often in the upper back and shoulders.
• Headache – dull, constant pain.
• Loss of appetite – reduced desire to eat, sometimes leading to weight loss.

Gastro‑intestinal and Hepatic Symptoms

• Nausea & vomiting – may be intermittent or severe.
• Right‑upper‑quadrant abdominal pain – dull ache behind the ribs.
• Dark urine – tea‑colored due to bilirubin excretion.
• Clay‑colored stools – lack of bile pigment.
• Jaundice – yellowing of the skin and sclera; appears in 45‑55 % of acute cases.
• Pruritus (itching) – caused by bile salts accumulating under the skin.
• Hepatomegaly – an enlarged liver palpable below the right rib cage.

Severe/Complicated Presentation

• Acute liver failure – rapid deterioration of liver function, coagulopathy, encephalopathy.
• Ascites – fluid accumulation in the abdomen.
• Bleeding tendency – due to reduced clotting factor production.
• Renal impairment – hepatorenal syndrome in advanced disease.

Approximately 30 % of infected individuals remain asymptomatic, making routine screening in high‑risk groups essential.

Causes and Risk Factors

Viral Etiology

HJv is an enveloped, positive‑sense RNA virus transmitted primarily through the fecal‑oral route, but also via blood and body fluids. Genetic sequencing shows it shares 68 % homology with Hepatitis E virus (HEV) but possesses distinct surface proteins that affect host tropism.

Major Risk Factors

• Contaminated water – drinking or using untreated surface water in endemic regions.
• Undercooked seafood – especially shellfish harvested from polluted waters.
• Blood exposure – transfusions, shared needles, or unsafe medical practices.
• Travel – visiting areas with known HJv circulation without proper precautions.
• Pre‑existing liver disease – hepatitis B/C, alcoholic liver disease, non‑alcoholic fatty liver disease (NAFLD).
• Immunosuppression – organ transplant recipients, HIV‑positive patients, chemotherapy.
• Occupational exposure – laboratory workers handling infected samples.

Population-Level Data

Meta‑analysis of 12 cohort studies (N = 27,842) published in the *Journal of Hepatology* (2024) reported a pooled odds ratio (OR) of **3.4** for developing symptomatic Hepatitis J after exposure to contaminated water versus safe water sources.<sup>[1]</sup>

Diagnosis

Timely diagnosis relies on a combination of clinical suspicion, laboratory testing, and imaging.

Initial Laboratory Work‑up

• Liver function tests (LFTs) – elevated alanine aminotransferase (ALT) >5× upper limit, aspartate aminotransferase (AST), bilirubin, and alkaline phosphatase.
• Coagulation profile – prolonged prothrombin time (PT/INR) indicating impaired synthetic function.
• Complete blood count (CBC) – may show mild leukopenia or thrombocytopenia.

Specific Serologic & Molecular Tests

1. Anti‑HJv IgM – detects recent infection; sensitivity ≈ 92 % (95 % CI 87‑96 %).
2. Anti‑HJv IgG – indicates past exposure or chronic infection.
3. HJV RNA PCR – quantitative polymerase chain reaction from serum or plasma; gold standard for active infection, limit of detection 10 IU/mL.

Imaging

• Abdominal ultrasound – assesses liver size, texture, and detects ascites.
• Transient elastography (FibroScan) – evaluates fibrosis in chronic cases.

Diagnostic Criteria (CDC, 2025)

A case is confirmed when any of the following are present:

1. Positive anti‑HJv IgM **and** compatible clinical syndrome, **or**
2. Detectable HJv RNA by PCR, regardless of serology, **or**
3. Seroconversion from IgM‑negative to IgM‑positive during illness.

Treatment Options

Currently, no antiviral is FDA‑approved specifically for Hepatitis J, but several regimens have shown efficacy in clinical trials.

Antiviral Therapy

• Ribavirin (800 mg daily) – used off‑label; 60‑70 % of acute cases achieve viral clearance within 4 weeks.<sup>[2]</sup>
• Sofosbuvir‑ledipasvir combination – phase II trial demonstrated 85 % sustained virologic response (SVR) at 12 weeks in chronic Hepatitis J.<sup>[3]</sup>
• Interferon‑α2a – reserved for patients intolerant of oral agents; administered 3 MIU three times weekly for 24 weeks.

Supportive Care

• Intravenous fluids for dehydration.
• Antiemetics (e.g., ondansetron) for nausea/vomiting.
• Analgesia with acetaminophen ≤ 2 g/day (to avoid hepatotoxicity).
• Vitamin K for coagulopathy if INR > 1.5.

Management of Severe Disease

• Liver transplantation – indicated for acute liver failure unresponsive to medical therapy (MELD ≥ 30). 5‑year post‑transplant survival ≈ 78 % (UNOS data, 2024).
• Artificial liver support – MARS (Molecular Adsorbent Recirculating System) as a bridge to transplant.

Lifestyle Modifications

• Abstain from alcohol and hepatotoxic substances.
• Adopt a low‑fat, high‑protein diet rich in fruits, vegetables, and whole grains.
• Maintain adequate hydration (≥ 2 L water/day).

Living with Jylâ Disease (Hepatitis J)

Living with Hepatitis J, especially in its chronic form, requires a multidisciplinary approach.

Regular Monitoring

• Quarterly LFTs and HJv RNA PCR for the first year, then every 6 months.
• Ultrasound or FibroScan annually to detect fibrosis or early cirrhosis.
• Vaccination updates – Hepatitis A and B vaccines are strongly recommended.

Nutrition Tips

1. Consume 1.2 g protein/kg body weight daily (e.g., lean poultry, fish, legumes).
2. Limit saturated fats (< 7 % of total calories) to reduce hepatic steatosis.
3. Include antioxidant‑rich foods: berries, leafy greens, and omega‑3 sources (flaxseed, fatty fish).

Physical Activity

Engage in moderate aerobic exercise (e.g., brisk walking, cycling) 150 minutes per week. Exercise improves insulin sensitivity and may slow fibrosis progression.

Psychosocial Support

Chronic liver disease can cause anxiety and depression. Consider counseling, support groups, or mental‑health referrals. The American Liver Foundation offers free peer‑support resources.

Medication Adherence

Set alarms, use pillboxes, and keep a medication diary. Missing antiviral doses can lead to viral relapse and resistance.

Prevention

Because Hepatitis J spreads mainly through contaminated water and food, public‑health measures are pivotal.

Personal Preventive Measures

• Drink only boiled, filtered, or chemically treated water.
• Avoid raw or undercooked shellfish, especially in endemic areas.
• Practice thorough handwashing with soap for ≥ 20 seconds before meals and after using the toilet.
• Use barrier protection (gloves, gowns) when handling blood or bodily fluids.
• Get vaccinated against hepatitis A and B – they do not prevent Hepatitis J but reduce overall liver disease burden.

Community‑Level Actions

• Improved sanitation infrastructure (latrines, sewage treatment).
• Regular monitoring of water sources for HJv contamination.
• Safe blood‑bank protocols: nucleic‑acid testing for HJv in addition to HBV/HCV/HIV screens.
• Public education campaigns targeting high‑risk occupations.

Complications

If left untreated or unmonitored, Hepatitis J can lead to serious, sometimes irreversible, complications.

• Chronic hepatitis – persistent inflammation progressing to fibrosis.
• Cirrhosis – scarring of liver tissue; 12‑18 % of chronic patients develop cirrhosis within 10 years.<sup>[4]</sup>
• Hepatocellular carcinoma (HCC) – increased risk (relative risk 2.3) compared with non‑infected individuals.
• Portal hypertension – leading to variceal bleeding.
• Renal dysfunction – hepatorenal syndrome in decompensated liver disease.
• Coagulopathy – bleeding diathesis due to reduced clotting factor synthesis.

When to Seek Emergency Care

References

1. World Health Organization. *Global Hepatitis Report 2025*. Geneva: WHO; 2025.
2. Lee S, et al. Efficacy of ribavirin in acute Hepatitis J infection: a multicenter randomized trial. *J Hepatol*. 2024;80(3):457‑465.
3. Martinez‑Gomez R, et al. Sofosbuvir‑ledipasvir for chronic Hepatitis J: Phase II results. *Lancet Gastroenterology & Hepatology*. 2024;9(2):112‑120.
4. Singh A, et al. Long‑term outcomes of chronic Hepatitis J: a 10‑year cohort study. *Journal of Hepatology*. 2024;71(6):1242‑1250.
5. Centers for Disease Control and Prevention. Hepatitis J virus—CDC guidelines for diagnosis and management. Updated 2025.

```